The FDA granted approval to the enVista Envy full range of vision IOLs following Canadian approval in May 2024.

According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks ...

A recent paper reveals increasing rates of diabetic retinopathy in young patients with diabetes, sparking concerns over ...

Artificial intelligence has the potential to improve ophthalmology practices by streamlining documentation, enhancing ...

The phase 3 clinical trial is a randomized, double-blind, three-arm study comparing MELT-300, sublingual midazolam, and ...

On World Sight Day, leading experts in ophthalmology look at artificial intelligence and how it could impact diagnosing and ...

Camp AAO offers childcare for children aged 6 months to 12 years, ensuring a safe environment near McCormick Place. The Saturday Night Celebration replaces the Orbital Gala, providing networking ...

Nanoscope plans to submit a BLA for MCO-010 in Q1 2025, following positive FDA feedback. MCO-010 is an optogenetic therapy for vision restoration in advanced retinitis pigmentosa, independent of gene ...

MJH Life Sciences, parent company of Ophthalmology Times, has acquired The EnVision Summit. The meeting, held annually in ...

Ten of the institute's ophthalmologists will present their work in more than 20 sessions with a wide range of topics ...

According to the company, the platform accompanies the launch of Qdata Retinitis Pigmentosa for life sciences and the ...